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Abstract
Nitric oxide–releasing aspirin (NO-aspirin) represents a novel class of promising chemopreventive agents. Unlike
conventional nonsteroidal anti-inflammatory drugs, NO-aspirin seems to be free of adverse effects while retaining
the beneficial activities of its parent compound. The effect of NO-aspirin on pancreatic carcinogenesis was inves-
tigated by assessing the development of precursor pancreatic lesions and adenocarcinomas in KrasG12D/+ trans-
genic mice that recapitulate human pancreatic cancer progression. Six-week-old male p48Cre/+–LSL-KrasG12D/+
transgenic mice (20 per group) were fed diets containing 0, 1000, or 2000 ppm NO-aspirin. The development of
pancreatic tumors was monitored by positron emission tomography imaging. All mice were killed at the age of
41 weeks and assessed for pancreatic intraepithelial neoplasia (PanIN) and pancreatic ductal adenocarcinoma
(PDAC) and for molecular changes in the tumors. Our results reveal that NO-aspirin at 1000 and 2000 ppm signif-
icantly suppressed pancreatic tumor weights, PDAC incidence, and carcinoma in situ (PanIN-3 lesions). The degree
of inhibition of PanIN-3 and carcinoma was more pronounced with NO-aspirin at 1000 ppm (58.8% and 48%,
respectively) than with 2000 ppm (47% and 20%, respectively). NO-aspirin at 1000 ppm significantly inhibited
the spread of carcinoma in the pancreas (∼97%; P < .0001). Decreased expression of cyclooxygenase (COX; with
∼42% inhibition of total COX activity), inducible nitric oxide synthase, proliferating cell nuclear antigen, Bcl-2, cyclin
D1, and β-catenin was observed, with induction of p21, p38, and p53 in the pancreas of NO-aspirin–treated mice.
These results suggest that low-dose NO-aspirin possesses inhibitory activity against pancreatic carcinogenesis by
modulating multiple molecular targets.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) remains a devastating and
almost uniformly lethal disease despite tremendous scientific efforts
for the past six decades. It has the worst prognosis and is the fourth
leading cause of cancer-related deaths in the United States, with a five-
year survival of <5% [1,2]. The high mortality rate is due, in part, to
Address all correspondence to: Dr. Chinthalapally V. Rao, Center for Cancer Prevention
and Drug Development, University of Oklahoma Health Sciences Center, 975 NE
10th Street, BRC Building II, Room 1203, Oklahoma City, OK 73104. E-mail:
cv-rao@ouhsc.edu
1We acknowledge the support from the National Cancer Institute (N01CN-53300).
2This article refers to supplementary material, which is designated by Figure W1 and is
available online at www.neoplasia.com.
Received 25 June 2012; Revised 25 June 2012; Accepted 10 July 2012
Copyright © 2012 Neoplasia Press, Inc. All rights reserved 1522-8002/12/$25.00
DOI 10.1593/neo.121026
www.neoplasia.com
Volume 14 Number 9 September 2012 pp. 778–787 778
the difficulties in establishing an early and accurate diagnosis as well as
to the lack of effective prevention treatments. The treatment strategies
for pancreatic carcinoma have been hampered significantly by a num-
ber of unique challenges like the first definitive diagnosis only at an
advanced stage [3–5]. Therefore, the stepwise progression of PDAC
development has been inaccessible for study, and the precursor cell
types still remain an area of active interest. One of the major goals
of the pancreatic cancer biomarker field is to improve patient survival
by developing effective chemoprevention and treatment strategies
enabled by a better understanding of the underlying etiological and
pathophysiological mechanisms. Oncogenic Kras mutation, mostly
at codon 12, is observed in more than 95% of patients with pre-
cancerous lesions of the pancreas and PDAC [3–5].
Development of genetically engineered mouse models of pancre-
atic adenocarcinomas that mimic human disease progression has facil-
itated better understanding of the molecular pathobiology and is
leading to the strategies for prevention and treatment [4,5]. To study
the role of the mutant Kras gene in the initiation of pancreatic carcino-
genesis, expression of the mutant allele specifically in the pancreatic
epithelial cells is achieved by crossing LSL-KrasG12D mice with p48Cre
mice that express Cre-recombinase from a pancreatic specific promoter.
The p48Cre/+–LSL-KrasG12D/+ mice develop pancreatic intraepithelial
neoplasia (PanIN) lesions (PanIN-1A, PanIN-1B and high-grade
PanIN-2 and PanIN-3) followed by progression to PDAC as mice
age [6–9].
Epidemiological studies have shown a decreased incidence of cancer
with long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs)
that inhibit cyclooxygenase (COX) enzymes in several organ sites
[10,11]. Overproduction of aberrant arachidonic acid (AA) metabo-
lites, cytokines, and growth factors, as well as the activation of their sig-
naling pathways are known to contribute to the inflammation and
tumorigenesis. Similar to many other malignant tissues, pancreatic
lesions also overexpress COX-2 [12,13].
Epidemiologic evidence on the use of NSAIDs on the incidence of
pancreatic cancer has been supported by observational studies [14–
17]. The use of aspirin was inversely associated with incidence of
pancreatic cancer (0.67) as per the Nutrition Examination Study 1
cohort. In another cohort study of patients with rheumatoid arthritis,
the age-standardized incidence ratios for pancreatic cancer were 1.12
for men, 0.68 for women, and 0.83 for both sexes. A statistically
nonsignificant inverse association between pancreatic cancer and
self-reported use of NSAIDs (mostly aspirin) was reported in one
case-control study. A meta-analysis with a total of 11 studies (3 case-
control studies, 7 cohort studies, and 1 randomized trial) involving
6386 pancreatic cancer cases does not indicate that use of aspirin or
NSAIDs affects the risk of pancreatic cancer [14–18]. Another recent
clinic-based case-control study showed that there is no risk of pancreatic
cancer on NSAID usage and that the use of aspirin for 1 day/month
was greatly associated with reduced risk of pancreatic cancer [19]. The
clinical usefulness of NSAIDs combined with their potentially life-
threatening toxicity has prompted intense efforts to improve their safety
profile. Nitric oxide (NO)–donating NSAIDs (NO-NSAID) represent
such an approach [20]. Conventional aspirin prevents human cancers,
but its toxicity precludes its application as a chemopreventive agent.
NO-releasing aspirin (NO-aspirin) consists of traditional aspirin bearing
–ONO2, which releases NO. NO-aspirin was shown to be superior in
efficacy and safety profile [20,21]. NO-aspirin was found to be >1000-
fold more potent and safer than aspirin in cultured human cancer cells
[22]. NO-aspirin was more potent than aspirin for the prevention of
several cancers [20,22–26]. Its safety has been documented, at least pre-
liminarily, in humans [27,28].
On the basis of these observations, we evaluated the chemopreven-
tive effect of NO-acetylsalicylic acid (ASA) against pancreatic cancer
using p48Cre/+–LSL-KrasG12D/+ transgenic mice that recapitulate
many morphologic and molecular features of the human disease.
Here, we report that NO-aspirin has potent chemopreventive prop-
erties and modulates key markers of pancreatic lesion progression.
Materials and Methods
Animals, Diets, and Care
All animal experiments were done in accordance with the institu-
tional guidelines of the American Council of Animal Care. Required
numbers of activated KrasG12D/+ mice were generated as described
below. Animals were housed in ventilated cages under standardized
conditions (21°C, 60% humidity, 12-hour light/12-hour dark cycle,
20 air changes/hour) in the University of Oklahoma Health Sciences
Center Rodent Barrier Facility. Semi-purified modified AIN-76A diet
ingredients were purchased from Bio-Serv, Inc. (Frenchtown, NJ).
NO-NSAID (NO-Aspirin) (Figure 1A) were procured from the
Division of Cancer Prevention, National Cancer Institute chemo-
prevention drug repository. NO-aspirin (1000 and 2000 ppm) was pre-
mixed with small quantities of casein and then blended into the diet
using a Hobart Mixer. Both control and experimental diets were
prepared weekly and stored in the cold room. Agent content in the
experimental diets was determined periodically in multiple samples
taken from the top, middle, and bottom portions of individual diet
preparations to verify uniform distribution.Mice were allowed ad libitum
access to the respective diets and automated tap water purified by
reverse osmosis.
Breeding and Genotyping Analysis
LSL-KrasG12D/+ and p48Cre/+ mice were maintained in a C57BL/6
heterozygous genetic background. LSL-KrasG12D/+ and p48cre/+ mice
were bred, and the male offspring of activated KrasG12D/+ (12%) were
generated at required quantities. The genotype of each pup was con-
firmed by tail DNA extraction and polymerase chain reaction (PCR)
as described elsewhere [8,9,29].
Bioassay: Efficacy of NO-Aspirin
Genotyped male p48Cre/+–LSL-KrasG12D/+ transgenic mice were
used in the efficacy study. The experimental protocol is summarized
in Figure 1B. Five-week-old mice were selected and randomized, so
that average body weights in each group were equal (n = 20/group
p48Cre/+–LSL-KrasG12D/+ mice and n = 12 C57BL/6 wild-type
mice), and were fed AIN-76A diet for 1 week. At 6 weeks of age,
mice were fed AIN-76A experimental diets containing 0, 1000, or
2000 ppm NO-aspirin (Figure 1A) until termination of the study.
Mice were routinely checked for signs of weight loss or any signs
of toxicity or any abnormalities. Food intake and body weight of
each animal were measured once weekly for the first 6 weeks and
then once a month until termination. After 35 weeks (∼9 months)
on experimental diets, all mice were killed by CO2 asphyxiation and
necropsied; pancreata were collected from all groups (Figure 1, C–F ),
weighed, and snap frozen in liquid nitrogen for further analysis.
Pancreata (head to tail) required for histopathologic identification of
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PanIN lesions and PDAC and for evaluation of various molecular
markers by immunohistochemistry (IHC; Figure 1, G–L) were fixed
in 10% neutral buffered formalin as previously described.
Positron Emission Tomography–Computed
Tomography Imaging
Positron emission tomography–computed tomography (PET-CT)
imaging was performed on C57Bl/6 wild-type and treated and
untreated p48Cre/+–LSL-KrasG12D/+ mice (n = 4) at the end of the
experiment. Radiolabeled [18F]fluorodeoxyglucose (FDG) was intra-
venously injected in mice through tail vein. The probe was allowed
to distribute for 2 hours before PET-CT imaging was performed.
Mice were anesthetized with 2% isoflurane in an oxygen stream
and positioned in the field of view of X-PET/X-O-CT machine
(GammaMedica-Ideas, Northridge, CA). A fly-mode CT was acquired
(2 minutes) to establish anatomic landmarks before repositioning the
animal for PET imaging. Approximately 20 minutes of list-mode
PET data were acquired. The acquired image data were reconstructed
using a filtered backprojection algorithm. Both PET and CT images
were fused together using Amira 3.1 software provided with the imag-
ing system (Figure 2).
Tissue Processing and Histologic Analysis of
PanIN Lesions and PDAC
Formalin-fixed, paraffin-embedded tissues were sectioned (4 μm)
and stained with hematoxylin and eosin. Twenty sections of each
pancreas were histologically evaluated by a pathologist blinded to
the experimental groups. PanIN lesions and carcinoma were classi-
fied according to histopathology criteria as recommended and previ-
ously published by our group [8,9,29]. Briefly, to quantify the
progression of PanIN lesions, the total number of ductal lesions
and their grade were determined (Figure 1, G–L ). Pancreatic ducts
of the entire fixed specimen (head, body, and tail of the pancreatic
sections) were analyzed for each animal. The relative proportion of
Figure 1. (A) Experimental design for preventive efficacy evaluation of NO-aspirin in male p48Cre/+–LSL-KrasG12D/+ mice. At 6 weeks of
age, groups (20/group activated p48Cre/+–LSL-KrasG12D/+ or 12/group wild-type) of mice were fed AIN-76A diets containing 0, 1000, or
2000 ppm NO-aspirin continuously for 35 weeks, and each pancreas was evaluated histopathologically for marker expressions as
described in the text. (B) Genotyping of p48Cre/+–LSL-KrasG12D/+ mice offspring by PCR (lanes 1 and 4 represent Cre, lanes 2, 5, 6, 8,
and 10 represent wild type, lane 11 represents Kras, and lanes 3, 7, and 9 represent activated Kras). Pancreata of (C) wild-type, (D and E)
untreated p48Cre/+–LSL-KrasG12D/+, and (F) NO-aspirin–treated p48Cre/+–LSL-KrasG12D/+ mice at 41 weeks of age. NO-aspirin treatment
significantly decreased the size of the pancreas compared to that of untreated mice. (G–L) Typical histologic appearance of the wild-type
pancreas (G), PanIN-1 lesions (H), PanIN-2 lesions (I), PanIN-3 lesions (J), carcinoma (K), and NO-aspirin–treated pancreas (L). No evidence
of PanINs or PDAC was seen in the pancreas of wild-type mice. Significant increase in the normally appearing pancreas was seen with
NO-aspirin treatment in p48Cre/+–LSL-KrasG12D/+ mice.
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each PanIN lesion grade to the overall number of analyzed ducts was
recorded for each animal. Similarly, pancreatic carcinoma and nor-
mal appearing pancreatic tissue were evaluated for all the animals.
Immunohistochemistry
The effects of NO-aspirin on expression of proliferating cell nuclear
antigen (PCNA), COX-2, β-catenin, and inducible nitric oxide
synthase (iNOS) were evaluated by IHC. Briefly, paraffin sections
were deparaffinized in xylene, rehydrated through graded ethanol
solutions, and washed in phosphate-buffered saline (PBS). Antigen
retrieval was carried out by heating sections in 0.01 M citrate buffer
(pH 6) for 30 minutes in a boiling water bath. Endogenous peroxi-
dase activity was quenched by incubation in 3% H2O2 in PBS for
5 minutes. Nonspecific binding sites were blocked using protein block
for 20 minutes. Sections were then incubated overnight at 4°C with
1:300 dilutions of monoclonal antibodies against PCNA, COX-2,
β-catenin, and iNOS (Abcam, Cambridge, MA and Santa Cruz Bio-
technology, Santa Cruz, CA). After several washes with PBS, the slides
were incubated with appropriate secondary antibody for 2 hours and
then washed and incubated with avidin-biotin complex reagent
(Zymed Laboratories, Camarillo, CA). After rinsing with PBS, the
slides were incubated with the chromogen 3, 3′-diaminobenzidine
for 3 minutes, then rinsed and counterstained with hematoxylin. Non-
immune rabbit immunoglobulins were substituted for primary anti-
bodies as negative controls. Slides were observed under an Olympus
microscope 1X701, and digital computer images were recorded with
an Olympus DP70 camera.
Analysis of COX-1/2 Activity Using Radio–High-Performance
Liquid Chromatography
Frozen pancreatic tumor tissues from male mice fed 1000 and
2000 ppm NO-aspirin and/or control diet were homogenized using
an ice-cold homogenizing buffer. The combined COX-1 and COX-2
activity assays were performed according to our previous published
methods [30]. Briefly, 150 μl of the reaction mixture containing
12 μM [14C]AA (420,000 dpm), 1 mM epinephrine, 1 mM gluta-
thione in 50 mM phosphate buffer (pH 7.4), and 30 mg of protein
for each assay was used. After incubation at 37°C for 20 minutes, the
reaction was terminated by adding 40 μl of 0.2 M HCl. The COX-
mediated metabolites of AA were extracted with ethyl acetate (3 ×
0.5 ml). The combined extracts were evaporated to dryness under
N2 and dissolved in 1 ml of acetonitrile, and 10-μl samples were
injected into a reversed-phase high-performance liquid chromatog-
raphy (HPLC) system (Shimadzu Scientific Instruments, Columbia,
MD) equipped with a Phenomenix C18 column (300 × 3.90 mm;
pore size, 10 μm). [14C]prostaglandins (PGs) and [14C]thromboxane
Figure 2. PET and CT images of wild-type and p48Cre/+–LSL-KrasG12D/+ mice (n = 4). The p48Cre/+–LSL-KrasG12D/+ mice were fed control
diet or control diet containing NO-aspirin for 35 weeks. The PET-CT imaging was performed at 41 weeks of age. About 2 hours before
imaging, FDG was intravenously injected into the mice through tail vein. Images are from wild-type, treated, and untreated p48Cre/+–LSL-
KrasG12D/+ mice. A significant accumulation of FDG was observed in the pancreas of untreated p48Cre/+–LSL-KrasG12D/+ mice, with a
significant decrease in the pancreas of the treated mice. Moreover, the wild-type mouse pancreas did not show any significant accu-
mulation of FDG.
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B2 (TXB2) were eluted with a gradient solvent system containing
solvent A [acetonitrile/water/acetic acid (35:65:0.1%)] and solvent B
[acetonitrile/water/acetic acid (65:30:0.1%)]. The eluted metabolites
were monitored and quantified with an IN/US Systems β-RAM
radio-HPLC detector. COX activities are presented as pmol [14C]AA
metabolized/mg protein per minute.
Western Blot Assay
Pancreata harvested from mice fed with or without NO-aspirin
were homogenized and lysed in ice-cold lysis buffer [50 mM Tris
(pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% NP40, 50 mM NaF,
1 mM sodium orthovanadate, 1 mM PMSF, 1 mM DTT, and 1×
protease inhibitor cocktail] (Sigma, St Louis, MO). After a brief vortex-
ing, the protein lysates were collected by centrifugation at 12,000g
for 15 minutes at 4°C, and protein concentrations were measured with
the Bio-Rad Protein Assay Reagent (Hercules, CA). Proteins (50 μg
protein/lane) were separated with 10% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and transferred to nitrocellulose
membranes. After blocking with 5% milk powder, membranes were
probed for expression of PCNA, p21, iNOS, COX-2, β-catenin, Bcl-2,
p53, and β-actin in hybridizing solution (1:500, in TBS–Tween 20
solution) using their respective primary antibodies (Cell Signaling
Technology [Danvers, MA], AbCam, and Santa Cruz Biotechnology)
and then probed with their respective horseradish peroxidase–conjugated
secondary antibodies. Detection was performed using the SuperSignal
West Pico Chemiluminescence procedure (Pierce, Rockford, IL). The
bands were captured on Ewen Parker Blue sensitive X-ray films and
quantified by densitometry as previously described [29].
RNA Extraction and Quantitative Reverse Transcription–PCR
Assay for Cyclin D1, p21, p38, and COX-2 mRNA Expressions
For cyclin D1, denaturation at 94°C for 3 minutes was followed by
35 cycles at 94°C for 30 seconds, 60°C for 20 seconds, and 72°C for
45 seconds. Oligonucleotide primer sequences used for the cyclin D1
gene were given as follows: 5′-ATGGAACACCAGCTCCTGTG-3′,
sense; 5′-ACCTCCAGCATCCAGGTGGC-3′, anti-sense. For p21,
denaturation at 94°C for 3 minutes was followed by 35 cycles at
94°C for 30 seconds, 60°C for 20 seconds, and 72°C for 45 seconds.
Oligonucleotide primer sequences used for p21 were given as follows:
5′-TCCTGGTGATGTCCGACCTG-3′, sense; 5′-TCCGTTTTCG-
GCCCTGAG-3′, anti-sense. For p38, denaturation at 94°C for 3 min-
utes was followed by 35 cycles at 94°C for 30 seconds, 60°C for
20 seconds, and 72°C for 45 seconds. Oligonucleotide primer
sequences used for p38 were given as follows: 5′-TATGTGCAGC-
CGCCCTCCCT-3′, sense; AGCAGTGTGCCCATGGCGTC, anti-
sense. For COX-2, denaturation at 94°C for 2 minutes was followed
by 35 cycles at 94°C for 30 seconds, 52°C for 30 seconds, and 72°C
for 1 minute. Oligonucleotide primer sequences used for COX-2 were
given as follows: 5′-CCTGTGCCTGATGATTGC-3′, sense; 5′-
CGGTGAAACTCTGGCTAG-3′, anti-sense. PCR was done using
the Taq polymerase, 10 mM deoxynucleoside triphosphates, and buffers
from Invitrogen (Carlsbad, CA). The PCR products were visualized and
photographed under UV illumination and quantified by densitometry.
Statistical Analysis
The data are presented as means ± SE. Differences in body weights
were analyzed by analysis of variance. Statistical differences between
control and treated groups were evaluated using Fisher’s exact test for
PDAC incidence, and unpaired t test with Welch’s correction was
used for PanINs and PDAC lesions. Differences between groups
are considered significant at P < .05.
Results
General Bioassay Observations
Both the p48Cre/+–LSL-KrasG12D/+ and wild-type C57/BL/6 mice
fed AIN-76A or NO-aspirin had steady body weight gains. As shown
in Figure 3A, there was no significant difference between body
weights in the mice fed either AIN-76A or diets supplemented with
either 1000 or 2000 ppm NO-aspirin. None of the animals fed the
NO-aspirin diets exhibited any observable toxicity or any gross mor-
phologic changes to liver, spleen, kidney, or lung despite notable dif-
ferences in pancreas weights. There were also no differences in the
amount of water or food consumption among the treatment and
control mice.
PET-CT Noninvasive Imaging of Pancreatic Tumors in Mice
To monitor the tumor progression and confirm the inhibitory
activity of NO-aspirin, we performed PET-CT imaging of the wild-
type and transgenic mice (n = 4) with or without NO-aspirin treatment
using FDG. Figure 2 shows the noninvasive PET-CT images of the
wild-type, positive, and treated transgenic mice at end of the experi-
ments. There was no tumor detected by this noninvasive imaging in
the wild-type mouse pancreas, whereas untreated KrasG12D/+ transgenic
mice accumulated high levels of FDG in the pancreas, confirming the
presence of metabolically active pancreatic tumor. The FDG accumu-
lation was significantly decreased in the pancreas of the treatment
group. The three-dimensional PET-CT images indicated that the
tumor growth rate was significantly inhibited in the treatment group
when compared to the nontreatment group (Figure 2).
Effect of NO-Aspirin on Pancreas Weight and Progression of
PanIN Lesions to PDAC in KrasG12D/+ Mice
Pancreatic weight is one of the important simple markers of
PDAC development. In the C57BL/6 wild-type mice, the average
pancreas weight was 0.28 g. However, a significant increase in pancreas
weight was observed in p48Cre/+–LSL-KrasG12D/+ mice (1.24 g), almost
five-fold more than the wild-type mouse pancreas (Figure 3B). A
significant decrease in pancreas weights (58.8%, P < .0002 and
49.2%, P < .002) was observed in KrasG12D/+ mice fed 1000 and
2000 ppm NO-aspirin diets, respectively (Figures 1, C–F , and 3B). In
addition, mice that were killed before termination (because of sickness)
or found dead were ∼20% (4 of 20 mice) in the control group. Low-
grade PanINs (1A and 1B) to high-grade PanINs (2 and 3) (Figure 1,
G–L) were observed in all the p48Cre/+–LSL-KrasG12D/+ mice fed either
AIN-76A diet alone or NO-aspirin diets. Extensive histopathologic
analysis suggests that no pathologic alteration was observed in wild-type
mice fed either AIN-76A or NO-aspirin–supplemented diets. The effi-
cacy end points used in this study were inhibition of PanINs and
PDAC. The criterion used for invasive disease is described in our earlier
reports [29].
Figure 3C summarizes the efficacy of NO-aspirin on PDAC
incidence in KrasG12D/+ mice. KrasG12D/+ induced an incidence of
85% (percentage of mice with PDAC, 17 of 20 mice developed
PDAC), whereas 1000 ppmNO-aspirin–fed mice showed an incidence
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of 35% PDAC (7 of 20 mice with PDAC) and 2000 ppmNO-aspirin–
fed mice had an incidence of 45% carcinoma (9 of 20 mice with
PDAC). Control diet–fed KrasG12D/+ mice developed, on the average,
about 62 PanIN-1, 51 PanIN-2, and 146 PanIN-3 lesions, whereas
mice fed dietary NO-aspirin at 1000 ppm for 35 weeks developed
about 75 PanIN-1, 107 PanIN-2, and 76 PanIN-3 lesions and those
fed 2000 ppm developed about 121 PanIN-1, 110 PanIN-2, and 116
PanIN-3 lesions, respectively (Figure 3D). Overall, we observed a
higher number of PanIN-1 and PanIN-2 lesions with the NO-aspirin
treatment when compared to control diet. Most importantly, the
carcinomas in situ, i.e., PanIN-3 lesions, were significantly reduced
(48% and 20%) with the 1000 and 2000 ppm NO-aspirin treatments,
respectively (Figure 3D), suggesting delay of progression. In addition,
control diet–fed mice showed about 49% of the pancreas with inva-
sive ductal carcinoma, whereas NO-aspirin–fed mice showed only
an average of 3.14% and 20.37% invasive ductal carcinoma, with
1000 and 2000 ppm, respectively (Figure 3E ). Furthermore, mice
fed 1000 or 2000 ppm NO-aspirin exhibited 30% and 24%, respec-
tively, normal appearing pancreatic tissue (free from the PanINs and
PDAC) in comparison to control diet–fed pancreas showing ∼2% to
be free from PanINs and PDAC (Figure 3F ).
Inhibition by NO-Aspirin of PCNA-Labeled Cell Proliferation
and COX-2 in PanINs and PDAC
NSAIDs exert their effects in part by inhibiting the cell prolifera-
tion, COX-2, and inducing apoptosis. Tumor cell proliferation was
measured by PCNA expression in pancreatic tumor tissues. As
shown in Figure 4, A to C , PCNA-labeled cells were decreased in
p48Cre/+-KrasG12D/+ mice fed NO-aspirin diets as compared with
mice fed control diet alone. As shown in Figure 4G , the proliferative
index (PI) was 83% in pancreatic tumor tissues of p48Cre/+–LSL-
KrasG12D/+ mice on control diet. Mice fed 1000 or 2000 ppm
Figure 3. (A) Effect of NO-aspirin on body weight (means ± SE, N = 13 or 12) at the termination of the experiment. No statistically
significant difference was observed between control and NO-aspirin–treated p48Cre/+–LSL-KrasG12D/+ or wild-type mice. (B) Effect of
NO-aspirin on pancreas weights at the termination. Low-dose NO-aspirin significantly reduced the pancreatic tumor weights compared
to high-dose NO-aspirin. (C) Effect of NO-aspirin on the incidence (percentage of mice with carcinomas) of PDAC. (D) Effect of NO-aspirin
on the PanIN multiplicity (means ± SE). (E) Percentage of carcinoma spread per pancreas. (F) Effect of NO-aspirin on normal pancreas.
The data in H to J were analyzed by unpaired t test with Welch’s correction; values are considered statistically significant at P < .05.
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NO-aspirin diet showed a decrease in PI by 41% and 33% (P <
.001–.0002), respectively (Figure 4G ). As shown in Figure 4, D to
F , high expression of COX-2 was observed in the PDAC of
KrasG12D/+ mice fed control diets. However, administration of 1000
and 2000 ppm NO-aspirin diet resulted in a significant decrease in
COX-2 protein expression levels in the pancreas (Figure 4, D–F ).
NO-Aspirin Inhibits Tumor COX Activity
A significant decrease was seen in total COX metabolites in the
pancreatic tumor of mice fed low-dose NO-aspirin diet, as deter-
mined with radio-HPLC analysis. However, 2000 ppm NO-aspirin
showed lesser inhibition. As shown in Figure 4H , mean total PGs
and TXB2 levels in control and 1000 and 2000 ppm treated pancreas
were 62.4, 36.43 (P < .0003), and 52.7 (15.5%; P < .01) pmol/mg
protein per minute, respectively (Figure 4H ).
Inhibition of β-Catenin, iNOS, PCNA, COX-2, Cyclin D1,
and Bcl-2 and Increase of p21, p38, and p53 by NO-Aspirin
Protein analysis by IHC and Western immunoblot analysis and/or
reverse transcription–PCR clearly demonstrated that pancreatic tis-
sues from NO-aspirin–fed mice had significantly lower expression
of β-catenin (Figures 5, A–C , and 6A ), iNOS (Figures 5, D–F ,
and 6A ), PCNA, COX-2, and Bcl-2 compared with pancreatic tis-
sues from mice fed control diet (Figures 4, D–F , and 6, A and B ).
Importantly, up-regulation of p21, p38, and p53 expressions were
observed in the pancreatic tumor tissues of NO-aspirin–fed mice
compared with control diet–fed mice (Figure 6, A and B ). The West-
ern blot results have been further confirmed by quantitative analysis
performed by densitometry of the blots (Figure W1).
Discussion
Epidemiological and clinical studies, as well as experimental studies,
suggest that NSAIDs are effective agents for cancer prevention.
COX-2 is overexpressed in both animal and human pancreatic cancers,
and several preventive and therapeutic strategies revolve around COX-2
as an important molecular target for chemoprevention [31]. Hence,
NSAIDs and COX-2–selective inhibitors have been widely tested for
cancer prevention, including that of pancreatic cancer. For example,
Funahashi et al. found that the selective COX-2 inhibitor nimesulide
delays the progression of pancreatic cancer precursor lesions in the
Figure 4. Effect of NO-aspirin on cell proliferation (A–C) and COX-2 (D–F) in pancreatic tumors. Immunohistochemical analysis was
performed with paraffin-embedded and microsectioned pancreatic tissues as described in Materials and Methods. Immunohistochem-
ical analysis of PCNA (A–C) and COX-2 (D–F) expression in PanIN lesions and in ductal cells. A significantly decreased expression of
PCNA and COX-2 was seen with low-dose NO-aspirin treatment. (G) Significant differences in PIs were observed between the groups.
(H) Effects of NO-aspirin on COX activity in the pancreas from mice as assessed with the radio-HPLC method. Values are means ± SEM,
N = 6 per treatment group. A significant (P < .006 and 0.0003) inhibition of AA metabolites (PGs and TXB2) was observed in the
NO-aspirin–treated group.
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KrasG12D mouse [32]. However, the gastrointestinal toxicities and
cardiovascular risks accompanying these agents have prompted a search
for novel approaches/agents devoid of unwanted side effects but with
similar or higher efficacies. In the present study, we have demonstrated
the chemopreventive effects of NO-aspirin against formation of PanIN
lesions and their progression to PDAC in p48Cre/+–LSL-KrasG12D/+
mice. This mouse model captures many significant features of human
pancreatic cancer development including aspects of histology, molecular
biology, and tumor biology and has been well justified for use in chemo-
prevention studies [8,29]. The delay of PanIN progression to PDAC in
the p48Cre/+–LSL-KrasG12D/+ mice shows the potential of NO-aspirin to
be an effective chemopreventive agent.We did not observe a dose depen-
dency. In fact, the lower dose of NO-aspirin appeared to be more pro-
tective than the higher dose. The reasons for the lack of better inhibitory
effects at higher doses needs further investigation.
Results also suggest that NO-aspirin delays the progression from
PanIN-1 and PanIN-2 lesions to PanIN-3 and PDAC (Figure 3).
Because only PanIN-3 are classified as carcinoma in situ, delaying
Figure 5. Effect of NO-aspirin on β-catenin (A–C) and iNOS (D–F) in pancreatic tumors. Immunohistochemical analysis was performed
with paraffin-embedded and microsectioned pancreatic tissues as described in Materials and Methods. (A–C) Immunohistochemical
analysis of β-catenin, PCNA, and iNOS (D–F) expression in PanIN lesions and in ductal cells. A significantly decreased expression of
β-catenin and iNOS expression was seen with low-dose NO-aspirin treatment.
Figure 6. (A) Effect of NO-aspirin on protein expression levels of p21, PCNA, iNOS, COX-2, β-catenin, Bcl-2, and p53 expression in PDAC.
Protein expression was analyzed by Western blot analysis as described in the text. (B) Effect of NO-aspirin on the mRNA expression
levels of cyclin D1, p21, p38, and COX-2 as determined with reverse transcription–PCR.
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the progression toward PDAC suggests a major impact on cancer
development. Of great interest has been the observation that the
long-term administration of NO-aspirin is not associated with overt
toxicity. Similar to the observations described here, we have shown pre-
viously that an epidermal growth factor receptor (EGFR) inhibitor and
atorvastatin inhibit Kras-activated development of PanINs and PDAC
[8,29]. This is the first report on the effect of NO-aspirin against pan-
creatic cancer in a mutant Kras mouse model. However, tumor efficacy
effects of NO-aspirin are not new; previously, NO-aspirin was tested
for efficacy against chemically induced pancreatic tumors in a hamster
model [33] and colon cancers in rats [34]; both studies supported the
chemopreventive property of this agent. Furthermore, low-dose NO-
aspirin inhibited spread of the carcinoma by 97% (Figure 2E), suggesting
that this agent may block invasiveness within the pancreas and further
metastasis to nearby organs. The bioassay protocol using PDAC as an
end point limited the comparative analysis of overall survival and rate of
metastasis in control diet and treatment groups.However, loss of 20%of
the mice on the control diets but not in the treated groups supports the
notion that NO-aspirin may increase survival by limiting metastasis.
An indirect insight into the mechanism underlying the cell kinetic
changes induced by NO-aspirin is provided by our study of the expres-
sion of p21WAF1/CIP1 [35]. p21 is activated by p53 to produce cell cycle
arrest in response to DNA damage. p21WAF1/CIP1 blocks cell cycle
progression, both by acting as a general inhibitor of cyclin dependent
kinase (Cdk)/cyclin complexes and by inhibiting DNA replication by
binding to PCNA, a subunit of DNA polymerase. We observed a sig-
nificant increase in p53 and p21 expressions in the low-dose–treated
NO-aspirin and reduced expression of tumor promoting markers cyclin
D1, β-catenin, COX-2, PCNA, and iNOS. Aspirin and NO-aspirin
treatments of colon cancer cells activated the p38 [mitogen-activated
protein kinase (MAPK)] pathway along with their respective down-
stream transcription factors such as c-Jun and activating transcription
factor 2 (ATF-2) [36,37]. Aspirin-induced p38 activation precedes
rapid ubiquitin-dependent cyclin D1 degradation [37]. Similarly, we
observed a dose-dependent increase in p38 and a decrease in cyclin
D1 mRNA expression in this study, suggesting that NO-aspirin causes
inhibition of cyclin D1 through the p38 MAPK pathway (Figure 6B).
We have previously reported that NO-NSAIDs including NO-
aspirin have strong inhibitory activity against colon carcinogenesis
associated with suppression of COX, iNOS, and β-catenin levels in
colon tumors [34]. Here, NO-aspirin showed a good suppression of
iNOS, COX-2, and β-catenin protein expressions (Figures 4, D–F ,
5, and 6A ) corresponding to inhibition of pancreatic tumorigenesis,
thereby confirming the previous results in colon cancer. The pro-
found effects of NO-aspirin on cell proliferation, cell cycle, and cell
death, combined with the role of MAPK cascades in these cellular
events that are critical to carcinogenesis, confirm our findings that
NO-aspirin acts, at least in part, by modulating this extensive signal
transduction system. Thus, it is apparent that NO-aspirin exerts
effects on multiple molecular targets in pancreatic cancer, perhaps
more than the present study has revealed. The actual contribution
of each of these changes to the chemopreventive effect of this agent
remains to be determined. As argued elsewhere regarding the mech-
anism of action of this compound [19], the choice between mecha-
nistic dominance (one pathway is sufficient for the effect) and
mechanistic redundancy (effects on multiple pathways are required)
is unresolved and our present study underscores this point.
In summary, our data indicate that NO-aspirin has significant
potential for pancreatic cancer prevention and possibly for treatment.
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Figure W1. Effect of NO-aspirin on protein expression levels of p21, PCNA, iNOS, COX-2, β-catenin, Bcl-2, and p53 expression in pan-
creatic ductal adenocarcinoma. Protein expression was analyzed by Western blot analysis as described in the text and quantified by
densitometry.
